This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health (CVS) Gets Final Approval to Close Aetna Deal
by Zacks Equity Research
Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.
4 Stocks to Buy as US Labor Market Reaches Full Potential
by Zacks Equity Research
An overly tight labor market could push wages up further, increasing consumer optimism around spending.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $75.07, marking a -0.6% move from the previous day.
Near-Term Outlook for Health Maintenance Organization Industry
by Zacks Equity Research
Retiring baby boomer population, new streams of revenues and consolidation paint a bright picture for the HMO industry.
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $80.34 in the latest trading session, marking a +0.64% move from the prior day.
CVS Health's (CVS) Q3 Earnings Top Estimate, Gross Margin Up
by Zacks Equity Research
CVS Health's (CVS) year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services.
Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR
by Ryan McQueeney
Ryan McQueeney chats with Dave Bartosiak about the near-term outlook for stocks after the midterm elections and the earnings outlook for Turtle Beach ahead of its report. The host also recaps earnings results from CVS, Eli Lilly, and Regeneron.
Stocks Gain Ahead of Midterm Results, But Where Are They Headed Next?
by Ryan McQueeney
U.S. stocks opened modestly higher on Tuesday, as investors kept a watchful eye on the historically tense midterm elections. Here's what market strategists are saying will happen after the midterms.
September JOLTS Report In Spotlight
by Zacks Equity Research
September JOLTS Report In Spotlight
Playing the Waiting Game; Plus MedTech, Pharma in Q3 Earnings
by Mark Vickery
We won't get the final numbers until later, so until then we're just playing the waiting game.
CVS Health (CVS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 1.17% and 0.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What to Expect from CVS Health's Q3 Earnings
by Benjamin Rains
Let's see what to expect from CVS before the opening bell Tuesday.
Should You Buy CVS Stock Ahead of Q3 Earnings?
by Benjamin Rains
Let's see if investors should think about buying CVS stock ahead of its Q3 financial results.
Upcoming Earnings Reports to Watch: CVS, QCOM, DIS
by Ryan McQueeney
Stocks were down in morning trading Friday, putting major indexes on track to snap a three-day winning streak that followed a brutal month of selling. But will next week's earnings results get the rebound back on track? Let's take a closer look at a few of the earnings announcements due during the week of November 5!
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $72.84, moving +0.61% from the previous trading session.
Will CVS Health's (CVS) PBM Strength Boost Q3 Earnings?
by Zacks Equity Research
Despite a challenging pricing scenario, CVS Health (CVS) is currently gaining on high level of service and execution as well as a competitive pricing along with unique integrated model.
Aetna (AET) Q3 Earnings Beat Estimates, Membership Increases
by Zacks Equity Research
Aetna (AET) earnings grow on revenue and membership gains.
CVS Health (CVS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $70.67, moving +1.23% from the previous trading session.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $73.72 in the latest trading session, marking a +0.9% move from the prior day.
Walgreens Boots (WBA) Stock Looks Like A Cheap, Solid Buy Right Now
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) jumped roughly 1.6% Monday as investors continue to dive in after it posted impressive fiscal fourth-quarter results late last week. Looking ahead, the pharmaceutical giant looks poised for strong growth and WBA stock seems like it might be worth buying right now.
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVS Health (CVS) Stock Moves -0.72%: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $78.92, marking a -0.72% move from the previous day.
Walgreens (WBA) Stock Sinks 1.7% Ahead of Q4 Earnings: What to Watch
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) slipped 1.7% during regular trading hours Wednesday in a sign that investors might be a tad bit nervous about the pharmacy and cosmetic giant's Q4 earnings results Thursday.
The Zacks Analyst Blog Highlights: JPMorgan, American Express, FedEx, PepsiCo and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, American Express, FedEx, PepsiCo and CVS